Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...

Moderna and Novo Nordisk are once again in the bad books of the U.K.’s drug marketing watchdog. | Moderna and Novo Nordisk ...

The U.S. faces a potential 'Quad-emic' with rising cases of flu, COVID, RSV, and norovirus. Older adults, especially those ...

Are you ready for artificial intelligence (AI)-driven mRNA vaccines?

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

A surge in respiratory illness is typical for this time of year, and the simultaneous outbreak of highly contagious norovirus is piling on to the public health risk. Commonly known as stomach flu, ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Alone and in combination with other lower respiratory tract disease signs and symptoms, dyspnea is the best predictor of severe RSV outcomes.